Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
- Resource Type
- Article
- Authors
- Hopkins, Robert J.; Howard, Cris; Hunter-Stitt, Ericka; Kaptur, Paulina E.; Pleune, Brett; Muse, Derek; Sheldon, Eric; Davis, Matthew; Strout, Cynthia; Vert-Wong, Katya
- Source
- Vaccine. Apr2014, Vol. 32 Issue 19, p2217-2224. 8p.
- Subject
- *MEDICATION safety
*DRUG dosage
*DRUG tolerance
*IMMUNOGENETICS
*CLINICAL trials
- Language
- ISSN
- 0264-410X
Highlights: [•] BioThrax was well tolerated. [•] The primary success criterion at Day 63 was met. [•] Key secondary success criteria at Day 70 and Days 63–100 were met. [ABSTRACT FROM AUTHOR]